MagForce AG: Newly launched 'NanoTherm(R) Therapy School' kicks off with successful first training session

Dow Jones received a payment from EQS/DGAP to publish this press release.

DGAP-Media / 2019-02-06 / 09:30 
 
MagForce AG: Newly launched _'NanoTherm(R) Therapy School'_ kicks off with 
successful first training session 
 
· _MagForce introduces practice-oriented, unique, multifaceted application 
training for the use of NanoTherm Therapy in treating brain tumors_ 
 
· Training concept developed in close partnership with leading experts 
Prof. Dr. Walter Stummer, PD Dr. Dr. Oliver Grauer, University Hospital 
Münster, and PD Dr. Johannes Wölfer, Hufeland Klinikum GmbH Mühlhausen 
 
*Berlin, Germany and Nevada, USA, February 06, 2019* - MagForce AG 
(Frankfurt, Scale, XETRA: MF6, ISIN: DE000A0HGQF5), a leading medical device 
company in the field of nanomedicine focused on oncology, is pleased to 
report the successful start of its newly launched _NanoTherm(R) Therapy 
School_ series, a comprehensive application training series consisting of 
three consecutive modules to certify surgeons in the use of the Company's 
innovative NanoTherm technology. The first session, "Module A - the basics", 
took place end of January, 2019 in Berlin. 
 
Targeted towards medical professionals working in the field of 
neuro-oncology, the _NanoTherm(R) Therapy School_ series aims at introducing 
participants to the theoretical knowledge and practical techniques required 
to successfully apply MagForce's NanoTherm technology for the treatment of 
brain tumors. In practicising their skills with human specimens, 
participants are able to familiarize themselves with the procedures and 
device usages in a stress-free environment under largely real operating 
conditions. 
 
The _NanoTherm(R) Therapy School_ is designed in three consecutive modules 
allowing participants to gain knowledge and understanding of the NanoTherm 
technology starting from basic application techniques (nanopasting) and 
building to advanced techniques and more experimental application forms in 
the final module. The practical section of the course is complemented by 
lectures on directly relevant aspects of Nano Therm therapy, as well as 
sample preparation and surgical videos. The equipment and facilities used 
during the course meet the requirements of today's state of the art surgical 
equipment. 
 
The training concept of _NanoTherm(R) Therapy School_ was developed in close 
collaboration with Prof. Dr. Walter Stummer, PD Dr. Dr. Oliver Grauer, 
University Hospital Münster, and PD Dr. Johannes Wölfer, Hufeland Klinikum 
GmbH Mühlhausen, drawing on their long-standing experience in the treatment 
of brain tumor patients with NanoTherm therapy. The course is supervised 
with a ratio of three students to one lecturer and one technician, ensuring 
maximum learning success. 
 
_"Simulation-based medical education enables knowledge and skill acquirement 
in a safe, educational orientated and efficient environment. Becoming 
acquainted with a new treatment method in a stress-free yet largely 
realistic setting is a great way to introduce physicians to a new treatment 
option and is key to ensuring that patients will receive the highest quality 
of treatment", _*said Prof. Dr. Walter Stummer, Director of the Department 
of Neurosurgery at the University Hospital Münster.* 
 
*Prof. Dr. med. habil. Jan-Peter Warnke, Director of the Department of 
Neurosurgery at the Chefarzt, Paracelcus Clinic Zwickau, participant of the 
Module A, added* "Innovation is extremely important in medicine and has 
served our patients well. Obtaining the appropriate training in new 
technologies and techniques is a vital part of adopting these advances into 
our standard treatment regimens. Practical trainings such as MagForce's 
NanoTherm(R) Therapy School are therefore very welcomed as they allow 
neurosurgeons to ease into the method while developing the necessary skills. 
The mixture of academic and practical experience paired with the 
instructors' and speakers' long-standing experience with the technique is 
what sets this course apart. Embracing new methods of teaching advanced 
technology helps bridge the learning gap from invention to patient usage." 
 
For more information about _NanoTherm Therapy(R) School_, please contact: 
Dipl.-Ing. Tobias Hanitsch ([e-mail]) 
Marcel Pilz ([e-mail]) 
 
*About MagForce AG and MagForce USA, Inc.* 
 
MagForce AG, listed in the Scale segment of the Frankfurt Stock Exchange 
(MF6, ISIN: DE000A0HGQF5), together with its subsidiary MagForce USA, Inc. 
is a leading medical device company in the field of nanomedicine focused on 
oncology. The Group's proprietary NanoTherm(R) therapy enables the targeted 
treatment of solid tumors through the intratumoral generation of heat via 
activation of superparamagnetic nanoparticles. 
 
NanoTherm(R), NanoPlan(R), and NanoActivator(R) are components of the 
therapy and have received EU-wide regulatory approval as medical devices for 
the treatment of brain tumors. MagForce, NanoTherm, NanoPlan, and 
NanoActivator are trademarks of MagForce AG in selected countries. 
 
*For more information, please visit: www.magforce.com [1]. 
Get to know our Technology: video (You Tube) [2] * 
*Stay informed and subscribe to our mailing list [3]* 
 
*Disclaimer * 
This release may contain forward-looking statements and information which 
may be identified by formulations using terms such as "expects", "aims", 
"anticipates", "intends", "plans", "believes", "seeks", "estimates" or 
"will". Such forward-looking statements are based on our current 
expectations and certain assumptions, which may be subject to a variety of 
risks and uncertainties. The results actually achieved by MagForce AG may 
substantially differ from these forward-looking statements. MagForce AG 
assumes no obligation to update these forward-looking statements or to 
correct them in case of developments, which differ from those, anticipated. 
 
*Contact:* 
Barbara von Frankenberg 
Vice President 
Communications & Investor Relations 
T [phone] 
E-Mail: [e-mail] 
 
End of Media Release 
 
Issuer: MagForce AG 
 
2019-02-06 Dissemination of a Press Release, transmitted by DGAP - a service 
of EQS Group AG. 
The issuer is solely responsible for the content of this announcement. 
 
The DGAP Distribution Services include Regulatory Announcements, 
Financial/Corporate News and Press Releases. 
Archive at www.dgap.de 
Language: English 
Company:  MagForce AG 
          Max-Planck-Straße 3 
          12489 Berlin 
          Germany 
Phone:    [phone] 
Fax:      [phone] 
E-mail:   [e-mail] 
Internet: www.magforce.com 
ISIN:     DE000A0HGQF5 
WKN:      A0HGQF 
Indices:  Scale 30 
Listed:   Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt 
          (Scale), Stuttgart, Tradegate Exchange 
 
End of News DGAP Media 
 
772781 2019-02-06 
 
 
1: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=8c9fb96f72ca3bbe10dd7f041cbe6fa6&application_id=772781&site_id=vwd&application_name=news 
2: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=fee20ce56f7c48d1562a60533ead43c9&application_id=772781&site_id=vwd&application_name=news 
3: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=f35fad65a8bc4664a072c1fef1651402&application_id=772781&site_id=vwd&application_name=news 
 

(END) Dow Jones Newswires

February 06, 2019 03:30 ET (08:30 GMT)